As many mammalian families of guanine nucleotide exchange factors impact the Ras activation cycle 39, this may be one mechanism by which RASGRF2 impacts STAD pathogenesis, and it is reasonable to speculate that targeting mechanisms of physiologic Ras activation may represent a novel approach in the treatment of KRAS-amplified cancers 40. This evidence concerns the gene RASGRF2 and cancer.